These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 10770637

  • 21. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
    Nakano K, Todo T, Chijiiwa K, Tanaka M.
    Mol Ther; 2001 Apr; 3(4):431-7. PubMed ID: 11319903
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ.
    Cancer Res; 1997 Apr 15; 57(8):1502-9. PubMed ID: 9108452
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
    Nakano K, Todo T, Zhao G, Yamaguchi K, Kuroki S, Cohen JB, Glorioso JC, Tanaka M.
    J Gene Med; 2005 May 15; 7(5):638-48. PubMed ID: 15754306
    [Abstract] [Full Text] [Related]

  • 27. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y.
    Cancer Gene Ther; 2002 Apr 15; 9(4):356-64. PubMed ID: 11960286
    [Abstract] [Full Text] [Related]

  • 28. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
    Cozzi PJ, Burke PB, Bhargav A, Heston WD, Huryk B, Scardino PT, Fong Y.
    Prostate; 2002 Oct 01; 53(2):95-100. PubMed ID: 12242723
    [Abstract] [Full Text] [Related]

  • 29. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T, Martuza RL, Dallman MJ, Rabkin SD.
    Cancer Res; 2001 Jan 01; 61(1):153-61. PubMed ID: 11196154
    [Abstract] [Full Text] [Related]

  • 30. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, Gonen M, Ebright MI, Culliford A, Gusani NJ, Fong Y.
    Cancer Gene Ther; 2006 Mar 01; 13(3):326-34. PubMed ID: 16138120
    [Abstract] [Full Text] [Related]

  • 31. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY, Rennie PS, Jia WW.
    Clin Cancer Res; 2009 Aug 15; 15(16):5126-35. PubMed ID: 19671871
    [Abstract] [Full Text] [Related]

  • 32. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
    Mullen JT, Donahue JM, Chandrasekhar S, Yoon SS, Liu W, Ellis LM, Nakamura H, Kasuya H, Pawlik TM, Tanabe KK.
    Cancer; 2004 Aug 15; 101(4):869-77. PubMed ID: 15305421
    [Abstract] [Full Text] [Related]

  • 33. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
    Teshigahara O, Goshima F, Takao K, Kohno S, Kimata H, Nakao A, Nishiyama Y.
    J Surg Oncol; 2004 Jan 15; 85(1):42-7. PubMed ID: 14696086
    [Abstract] [Full Text] [Related]

  • 34. Infection and replication of herpes simplex virus type 1 in an organotypic epithelial culture system.
    Visalli RJ, Courtney RJ, Meyers C.
    Virology; 1997 Apr 14; 230(2):236-43. PubMed ID: 9143279
    [Abstract] [Full Text] [Related]

  • 35. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
    Fu X, Tao L, Cai R, Prigge J, Zhang X.
    Mol Ther; 2006 May 14; 13(5):882-90. PubMed ID: 16569513
    [Abstract] [Full Text] [Related]

  • 36. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model.
    Lambright ES, Kang EH, Force S, Lanuti M, Caparrelli D, Kaiser LR, Albelda SM, Molnar-Kimber KL.
    Mol Ther; 2000 Oct 14; 2(4):387-93. PubMed ID: 11020355
    [Abstract] [Full Text] [Related]

  • 37. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
    Rancourt C, Bergeron C, Lane D, Garon G, Piché A.
    Cytotherapy; 2003 Oct 14; 5(6):509-22. PubMed ID: 14660047
    [Abstract] [Full Text] [Related]

  • 38. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.
    Taneja S, MacGregor J, Markus S, Ha S, Mohr I.
    Proc Natl Acad Sci U S A; 2001 Jul 17; 98(15):8804-8. PubMed ID: 11438715
    [Abstract] [Full Text] [Related]

  • 39. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
    Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RC, Zhang X.
    Clin Cancer Res; 2003 Jul 17; 9(7):2727-33. PubMed ID: 12855653
    [Abstract] [Full Text] [Related]

  • 40. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.
    Cinatl J, Michaelis M, Driever PH, Cinatl J, Hrabeta J, Suhan T, Doerr HW, Vogel JU.
    Neoplasia; 2004 Jul 17; 6(6):725-35. PubMed ID: 15720798
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.